Porton Pharma Solutions Ltd.

Equities

300363

CNE100001S57

Pharmaceuticals

End-of-day quote Shenzhen S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
18.17 CNY +0.17% Intraday chart for Porton Pharma Solutions Ltd. -11.32% -27.75%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tranche Update on Porton Pharma Solutions Ltd.'s Equity Buyback Plan announced on October 28, 2023. CI
Porton Pharma Solutions Ltd. announces an Equity Buyback for CNY 30 million worth of its shares. CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Porton Pharma Solutions Ltd. authorizes a Buyback Plan. CI
Porton Pharma Solutions Ltd. agreed to acquire 30% stake in Hubei Yuyang Pharmaceutical Co., Ltd. for CNY73.5 million. CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Porton Pharma Solutions Ltd. Announces Final Dividend for the Year 2022, Payable on 09 May 2023 CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Porton Pharma Solutions Ltd. Approves Cash Dividend for the Year 2022 CI
Porton Pharma Sees Up to 25% Profit Drop in Q1 on Lower Orders MT
Porton Pharma Solutions Ltd. Proposes Profit Distribution for 2022 CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Porton Pharma to Build 2.5 Billion Yuan Drug R&D, Production Facility MT
Tranche Update on Porton Pharma Solutions Ltd.'s Equity Buyback Plan announced on August 4, 2022. CI
Porton Pharma Solutions Ltd.'s Equity Buyback announced on August 4, 2022, has closed with 2,022,344 shares, representing 0.37% for CNY 100 million. CI
Shanghai Feiteng Pharmaceutical Technology Co., Ltd. announced that it has received CNY 60 million in funding from Porton Pharma Solutions Ltd. CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tranche Update on Porton Pharma Solutions Ltd.'s Equity Buyback Plan announced on August 4, 2022. CI
Porton Pharma Solutions Ltd.(XSEC:300363) added to S&P Global BMI Index CI
Porton Pharma Solutions Ltd.(XSEC:300363) added to FTSE All-World Index CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Porton Advanced Solutions announced that it has received $80 million in funding from a group of investors CI
Porton Pharma Solutions Ltd. announces an Equity Buyback for CNY 100 million worth of its shares. CI
Porton Pharma Solutions Ltd. authorizes a Buyback Plan. CI
Porton Pharma Solutions Ltd.(SZSE:300363) added to Shenzhen Stock Exchange Component A Share Index CI
Chart Porton Pharma Solutions Ltd.
More charts
Porton Pharma Solutions Ltd., formerly Porton Fine Chemicals Ltd., is a China-based company principally engaged in the provision of customized pharmaceutical research and production services. The Company is also engaged in the multi-client product manufacturing businesses and pharmaceutical and chemical commerce businesses. The products of the Company include anti-viral, anti-diabetic, hypolipidemic, anti-cancer, anesthesia analgesia and anti-bacterial pharmaceuticals, among others. The Company operates its businesses in Europe, North America, Asia and China, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
18.17 CNY
Average target price
28.5 CNY
Spread / Average Target
+56.85%
Consensus

Quarterly revenue - Rate of surprise